Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari

Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.